5.24
-0.34(-6.09%)
Currency In USD
| Previous Close | 5.58 |
| Open | 5.58 |
| Day High | 5.63 |
| Day Low | 5.21 |
| 52-Week High | 8.51 |
| 52-Week Low | 1.92 |
| Volume | 26,694 |
| Average Volume | 70,337 |
| Market Cap | 150.2M |
| PE | -1.63 |
| EPS | -3.21 |
| Moving Average 50 Days | 5.51 |
| Moving Average 200 Days | 3.61 |
| Change | -0.34 |
If you invested $1000 in Insight Molecular Diagnostics Inc. (IMDX) 10 years ago, it would be worth $32.43 as of December 07, 2025 at a share price of $5.24. Whereas If you bought $1000 worth of Insight Molecular Diagnostics Inc. (IMDX) shares 5 years ago, it would be worth $132.32 as of December 07, 2025 at a share price of $5.24.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
NASHVILLE, Tenn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 10, 2025. iMDx will
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
GlobeNewswire Inc.
Oct 13, 2025 8:05 PM GMT
Steven Tahmooressi to lead global marketing efforts for GraftAssure family of assays and future productsBrings 25 years of experience driving new product adoption across geographies in transplantation, oncology and immunology NASHVILLE, Tenn., Oct.
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
GlobeNewswire Inc.
Oct 06, 2025 11:15 AM GMT
American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid overtreatment and preserve patient’s imm